L. Z. Bolieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
L. Z. Bolieva has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrij Alekseevitch Sychev
Petrovsky National Research Centre of Surgery; Russian Medical Academy of Continuous Professional Education
3 shared publications - M. S.-Kh. Sozaeva
Republican Clinical Hospital
3 shared publications - Sherzod Pardaboevich Abdullaev
Petrovsky National Research Center of Surgery, Moscow 119435, Russia
3 shared publications - Aleksander V. Gorelov
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Alexey Vadimovich Zilov
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Anastasiya A. Kachanova
Russian Medical Academy of Continuous Professional Education
2 shared publications
Latest Publications
- 22 October 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (3) , 33-38
Results of an open-label, randomized, multicenter, comparative study of clinical efficacy and safety of Pulmibud drug and Pulmicort drug in patients with partially controlled and uncontrolled persistent bronchial asthma
A prospective, open-label, randomized, multicenter, comparative, phase III study was performed for the purpose of evaluating non-inferiority and safety of «Pulmibud» budesonide inhalation suspension (AO «AKRIKHIN», Russia) in comparison with Pulmicort reference product (AstraZeneka) in patients with partially controlled and uncontrolled persistent bronchial asthma. Materials and methods. The study included 160 patients randomized into two equal groups (n=80): «Pulmibud» group and Pulmicort group. The primary efficacy endpoint was the dynamics of the mean incremental FEV1 on the 84th day of therapy compared to the baseline. The margin of non-inferiority amounted to 200 ml, which corresponds to the upper range of clinically significant difference for adult patients with asthma. Results. Similar changes in the primary and secondary endpoints have been achieved in all groups: mean increase of FEV1 was 111.4±376.1 ml in the «Pulmibud» group and 122.1±372.4 ml in the Pulmicort group (difference —10.7±109.6 ml; p=0.9315), which confirmed the non-inferiority hypothesis. The safety profile was also comparable: 50 adverse events (31.25% of patients) in the «Pulmibud» group and 52 (30.00%) in the Pulmicort group. Conclusion. The study results demonstrate the therapeutic equivalence of «Pulmibud» generic drug and original Pulmicort in adult patients with persistent bronchial asthma.
- 22 October 2025
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 1 (3) , 33-38
Results of an open-label, randomized, multicenter, comparative study of clinical efficacy and safety of Pulmibud drug and Pulmicort drug in patients with partially controlled and uncontrolled persistent bronchial asthma
A prospective, open-label, randomized, multicenter, comparative, phase III study was performed for the purpose of evaluating non-inferiority and safety of «Pulmibud» budesonide inhalation suspension (AO «AKRIKHIN», Russia) in comparison with Pulmicort reference product (AstraZeneka) in patients with partially controlled and uncontrolled persistent bronchial asthma. Materials and methods. The study included 160 patients randomized into two equal groups (n=80): «Pulmibud» group and Pulmicort group. The primary efficacy endpoint was the dynamics of the mean incremental FEV1 on the 84th day of therapy compared to the baseline. The margin of non-inferiority amounted to 200 ml, which corresponds to the upper range of clinically significant difference for adult patients with asthma. Results. Similar changes in the primary and secondary endpoints have been achieved in all groups: mean increase of FEV1 was 111.4±376.1 ml in the «Pulmibud» group and 122.1±372.4 ml in the Pulmicort group (difference —10.7±109.6 ml; p=0.9315), which confirmed the non-inferiority hypothesis. The safety profile was also comparable: 50 adverse events (31.25% of patients) in the «Pulmibud» group and 52 (30.00%) in the Pulmicort group. Conclusion. The study results demonstrate the therapeutic equivalence of «Pulmibud» generic drug and original Pulmicort in adult patients with persistent bronchial asthma.
- Open Access
- 7 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (6) , 420-430
Prevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
Drug sensitivity to, in particular to favipiravir, may vary among representatives of different ethnic groups. Studies have previously shown that carrying certain variants of the AOX1 and CYP1A2 genes may be associated with an increased incidence of adverse reactions with patients having COVID-19 and taking favipiravir. This work is devoted to studying the prevalence of mutant variants rs55754655 and rs10931910 of the AOX1 gene and rs762551 of the CYP1A2 gene in various ethnic groups of the North Caucasus.The aim. To characterize the distribution structure of AOX1 (rs55754655 and rs10931910) and CYP1A2 (rs762551) variants among the peoples of the North Caucasus (Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins).Materials and methods. The frequency of distribution of AOX1 and CYP1A2 gene variants was studied among 897 conditionally healthy volunteers (362 men — 40.4% and 535 women — 59.6%; average age — 34.6±6.3%), from 8 ethnic groups of the North Caucasus: Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins (n=100 for each), as well as 97 Russians (reference group).Results. As a result of the analysis, a significant difference was found in the allele frequencies for the rs10931910 AOX1 genetic polymorphism between Balkars and Russians (p p p CYP1A2 gene were found in the comparative analysis of ethnic groups with the comparison group.Conclusion. Significant differences were revealed in the frequency of AOX1 polymorphisms (rs10931910, rs55754655) in the peoples of the North Caucasus relative to the Russian population. The largest deviations were recorded in Dargins: a decrease in the frequency of the minor allele rs10931910 to 28.5% (p p=0.0105). The results may be useful for optimizing therapy with medicines that are AOX1 substrates, which include favipiravir, used to treat patients with COVID-19.
- 7 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 12 (6) , 420-430
Open AccessPrevalence of AOX1 and CYP1A2 gene polymorphisms associated with response to favipiravir therapy in novel coronavirus infection COVID-19 among ethnic groups of the North Caucasus
Drug sensitivity to, in particular to favipiravir, may vary among representatives of different ethnic groups. Studies have previously shown that carrying certain variants of the AOX1 and CYP1A2 genes may be associated with an increased incidence of adverse reactions with patients having COVID-19 and taking favipiravir. This work is devoted to studying the prevalence of mutant variants rs55754655 and rs10931910 of the AOX1 gene and rs762551 of the CYP1A2 gene in various ethnic groups of the North Caucasus.The aim. To characterize the distribution structure of AOX1 (rs55754655 and rs10931910) and CYP1A2 (rs762551) variants among the peoples of the North Caucasus (Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins).Materials and methods. The frequency of distribution of AOX1 and CYP1A2 gene variants was studied among 897 conditionally healthy volunteers (362 men — 40.4% and 535 women — 59.6%; average age — 34.6±6.3%), from 8 ethnic groups of the North Caucasus: Ossetians, Balkars, Kabardians, Avars, Dargins, Laks, Kumyks and Lezgins (n=100 for each), as well as 97 Russians (reference group).Results. As a result of the analysis, a significant difference was found in the allele frequencies for the rs10931910 AOX1 genetic polymorphism between Balkars and Russians (p p p CYP1A2 gene were found in the comparative analysis of ethnic groups with the comparison group.Conclusion. Significant differences were revealed in the frequency of AOX1 polymorphisms (rs10931910, rs55754655) in the peoples of the North Caucasus relative to the Russian population. The largest deviations were recorded in Dargins: a decrease in the frequency of the minor allele rs10931910 to 28.5% (p p=0.0105). The results may be useful for optimizing therapy with medicines that are AOX1 substrates, which include favipiravir, used to treat patients with COVID-19.
- Open Access
- 24 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 40-47
All-Russian observational non-interventional program on the study of the efficacy of Subetta in real-world clinical practice in patients with prediabetes (SILA)
Introduction. Treatment of type 2 diabetes mellitus (T2DM) and its complications impose a substantial economic burden on the healthcare system. Timely and high-quality follow-up monitoring of patients with prediabetes by primary care physicians helps prevent the development of diabetes mellitus and the progression of complications.Aim. To evaluate the experience of the use of Subetta in real-world clinical practice in patients with prediabetes. https://doi.org/10.21518/ms2025-128Materials and methods. A 3-month Subetta monotherapy was assessed in 1,101 patients with verified prediabetes who had not previously received antidiabetic treatment. The follow-up monitoring period was 12 weeks, during which the patients received Subetta at a dose of 2 tablets twice a day. The primary efficacy endpoints included changes in fasting plasma glucose levels, glycated hemoglobin (HbA1c) levels and OGTT two-hour blood glucose levels as compared with baseline values 3 months after Subetta therapy.Results. The 12-week Subetta therapy showed a significant decrease in all studied carbohydrate metabolism parameters. The average decrease in HbA1c levels among all patients with prediabetes was 0.3% (p < 0.001). Over the follow-up period, OGTT two-hour blood glucose levels decreased by an average of 0.87 mmol/l (p < 0.001). The average fasting glucose level decrease was 0.62 mmol/l (p < 0.001). This therapy had a high safety profile, as only 8 adverse events were recorded in 5 patients (0.5% of cases) during the study.Conclusions. The study demonstrated high efficacy and a favourable safety profile of Subetta in monotherapy of patients with prediabetes. After 3 months of treatment, normoglycemia state based on the OGTT two-hour blood glucose levels was achieved in approximately 70% of patients.
- 24 May 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 6,p. 40-47
Open AccessAll-Russian observational non-interventional program on the study of the efficacy of Subetta in real-world clinical practice in patients with prediabetes (SILA)
Introduction. Treatment of type 2 diabetes mellitus (T2DM) and its complications impose a substantial economic burden on the healthcare system. Timely and high-quality follow-up monitoring of patients with prediabetes by primary care physicians helps prevent the development of diabetes mellitus and the progression of complications.Aim. To evaluate the experience of the use of Subetta in real-world clinical practice in patients with prediabetes. https://doi.org/10.21518/ms2025-128Materials and methods. A 3-month Subetta monotherapy was assessed in 1,101 patients with verified prediabetes who had not previously received antidiabetic treatment. The follow-up monitoring period was 12 weeks, during which the patients received Subetta at a dose of 2 tablets twice a day. The primary efficacy endpoints included changes in fasting plasma glucose levels, glycated hemoglobin (HbA1c) levels and OGTT two-hour blood glucose levels as compared with baseline values 3 months after Subetta therapy.Results. The 12-week Subetta therapy showed a significant decrease in all studied carbohydrate metabolism parameters. The average decrease in HbA1c levels among all patients with prediabetes was 0.3% (p < 0.001). Over the follow-up period, OGTT two-hour blood glucose levels decreased by an average of 0.87 mmol/l (p < 0.001). The average fasting glucose level decrease was 0.62 mmol/l (p < 0.001). This therapy had a high safety profile, as only 8 adverse events were recorded in 5 patients (0.5% of cases) during the study.Conclusions. The study demonstrated high efficacy and a favourable safety profile of Subetta in monotherapy of patients with prediabetes. After 3 months of treatment, normoglycemia state based on the OGTT two-hour blood glucose levels was achieved in approximately 70% of patients.
- Open Access
- 28 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 144-150
Current opportunities for the prevention and treatment of carbohydrate metabolism disorders
Diabetes mellitus poses a significant threat to the health and lives of people worldwide. Consequently, the timely identification of individuals at risk and the prevention of disease development are of utmost importance. Increasing physical activity, reducing body weight, and quitting smoking are effective measures for preventing type 2 diabetes. When lifestyle modifications are insufficient, pharmacological glucose-lowering therapy is prescribed. The endocrinologist’s arsenal is dominated by drugs that have a predominant effect on hyperglycemia. Metformin is the 1st line of therapy for disorders of carbohydrate metabolism. It is known that insulin resistance is the main cause of the development and progression of complications of diabetes mellitus. Correction of insulin resistance looks like a promising drug tactic. However, the choice of a drug for these purposes is currently limited. Currently, new, promising drugs are being developed that can increase tissue sensitivity to insulin. Subetta is an original insulin sensitizer that helps to enhance insulin-dependent glucose metabolism. This is a complex drug that increases the sensitivity of tissues to insulin, and normalizes the function of the vascular endothelium, as well as helps to increase the level of adiponectin. A decrease in glycemic parameters, a reduction of the insulin resistance index (HOMA-index) and weight stabilization has been shown in the clinical studies. All-Russian observational non-interventional study is planned to assess the effectiveness of Subetta in real-world clinical practice for patients with prediabetes or type 2 diabetes (SILA). The study includes data from 2,500 patients approximately over the age of 18. The findings of this programme enable a comprehensive evaluation of the effectiveness of combined glucose-lowering therapy in conjunction with Subetta, based on the dynamic assessment of both clinical and laboratory parameters, as well as quality of life questionnaires.
- 28 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 144-150
Open AccessCurrent opportunities for the prevention and treatment of carbohydrate metabolism disorders
Diabetes mellitus poses a significant threat to the health and lives of people worldwide. Consequently, the timely identification of individuals at risk and the prevention of disease development are of utmost importance. Increasing physical activity, reducing body weight, and quitting smoking are effective measures for preventing type 2 diabetes. When lifestyle modifications are insufficient, pharmacological glucose-lowering therapy is prescribed. The endocrinologist’s arsenal is dominated by drugs that have a predominant effect on hyperglycemia. Metformin is the 1st line of therapy for disorders of carbohydrate metabolism. It is known that insulin resistance is the main cause of the development and progression of complications of diabetes mellitus. Correction of insulin resistance looks like a promising drug tactic. However, the choice of a drug for these purposes is currently limited. Currently, new, promising drugs are being developed that can increase tissue sensitivity to insulin. Subetta is an original insulin sensitizer that helps to enhance insulin-dependent glucose metabolism. This is a complex drug that increases the sensitivity of tissues to insulin, and normalizes the function of the vascular endothelium, as well as helps to increase the level of adiponectin. A decrease in glycemic parameters, a reduction of the insulin resistance index (HOMA-index) and weight stabilization has been shown in the clinical studies. All-Russian observational non-interventional study is planned to assess the effectiveness of Subetta in real-world clinical practice for patients with prediabetes or type 2 diabetes (SILA). The study includes data from 2,500 patients approximately over the age of 18. The findings of this programme enable a comprehensive evaluation of the effectiveness of combined glucose-lowering therapy in conjunction with Subetta, based on the dynamic assessment of both clinical and laboratory parameters, as well as quality of life questionnaires.
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 13 (3)
The impact of infection on micronutrient status: the role of vitamins and trace elements in defense against infection
Влияние инфекции на микронутриентный статус: роль витаминов и микроэлементов в противоинфекционной защите
- 1 January 2024
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 13 (3)
Open AccessThe impact of infection on micronutrient status: the role of vitamins and trace elements in defense against infection
Влияние инфекции на микронутриентный статус: роль витаминов и микроэлементов в противоинфекционной защите
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 13 (3)
The use of acetylsalicylic acid medications in the management of common cold and influenza in adults: safety implications
Место препаратов ацетилсалициловой кислоты в лечении острых респираторных вирусных инфекций и гриппа у взрослых: вопросы безопасности
- 1 January 2024
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 13 (3)
Open AccessThe use of acetylsalicylic acid medications in the management of common cold and influenza in adults: safety implications
Место препаратов ацетилсалициловой кислоты в лечении острых респираторных вирусных инфекций и гриппа у взрослых: вопросы безопасности
- Open Access
- 19 February 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (1) , 60-67
Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) and PTGS2 (rs20417) among residents of the North Caucasus.Patients and methods. The study involved 676 volunteers from Russian, Balkar, Kabardian and Ossetian ethnic groups. Carriage of polymorphic markers CYP2C8, PTGS1 and PTGS2 was determined using real-time polymerase chain reaction.Results and discussion. There were no significant differences between the groups in the rs10509681 and rs11572080 variants of the CYP2C8 gene. In all groups, the carriage of a combination of CYP2C8 and CYP2C9 alleles, encoding the phenotype of normal metabolizers, prevailed with a frequency of about 75% or more. The rs10306135 variant of the PTGS1 gene was found in 5.9% of Russians, 1.1% of Balkars, 5.3% of Kabardians, and 10.6% of Ossetians; variant rs12353214 – in 19.1; 9.4; 10.8 and 9.2%, rs20417 polymorphism of the PTGS2 gene in 0.4; 5; 2.8 and 3.1% respectively.Conclusion. The data obtained can be used to develop a more rational approach to the prescription of NSAIDs, taking into account the genetic characteristics of the local population in ethnic regions.
- 19 February 2022
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 16 (1) , 60-67
Open AccessStructure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) and PTGS2 (rs20417) among residents of the North Caucasus.Patients and methods. The study involved 676 volunteers from Russian, Balkar, Kabardian and Ossetian ethnic groups. Carriage of polymorphic markers CYP2C8, PTGS1 and PTGS2 was determined using real-time polymerase chain reaction.Results and discussion. There were no significant differences between the groups in the rs10509681 and rs11572080 variants of the CYP2C8 gene. In all groups, the carriage of a combination of CYP2C8 and CYP2C9 alleles, encoding the phenotype of normal metabolizers, prevailed with a frequency of about 75% or more. The rs10306135 variant of the PTGS1 gene was found in 5.9% of Russians, 1.1% of Balkars, 5.3% of Kabardians, and 10.6% of Ossetians; variant rs12353214 – in 19.1; 9.4; 10.8 and 9.2%, rs20417 polymorphism of the PTGS2 gene in 0.4; 5; 2.8 and 3.1% respectively.Conclusion. The data obtained can be used to develop a more rational approach to the prescription of NSAIDs, taking into account the genetic characteristics of the local population in ethnic regions.
- Open Access
- 3 September 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (8) , 43-51
Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation
Aim. To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation. Materials and methods. The study included 1446 conditionally healthy volunteers from 9 ethnic groups. Carriage of polymorphic TPMT and DPYD gene markers was detected by the Real-Time PCR (polymerase chain reaction) method. Results. In all ethnic groups, the distribution of genotypes and alleles matched the equilibrium of Hardy-Weinberg. TPMT*3A (rs1800460) and TPMT*3C (rs1142345) were observed in heterozygous state in all investigated ethnic groups. In the Kabardinian group (n=204) the frequency of the TPMT*3A minor allele (MAF, %) was 2.94%; Balkars (n=200) 1.25%; Ossetians (n=239) 1.67%; Chuvashes (n=238) 1.89%: Mari (n=206) 1.21%; Tatars (n=141) 1.77%; Russians (n=134) 4.85%. The frequency of the TPMT*3C minor allele (MAF, %) in the Kabardinian group (n=204) MAF was 4.90%; Balkars (n=200) 1. 75%; Buryats (n=114) 0.44%; Ossetians (n=239) 1.88%; Chuvashes (n=238) 1.68%: Mari (n=206) 1.21%; Tatars (n=141) 1.42%; Russians (n=134) 4.48%. The results of the analysis of DPYD*2A polymorphism (rs3918290) demonstrated ethnic peculiarities of distribution. In the heterozygous state it was found only in the groups of Kabardins (n=204, MAF 1.22%), Balkars (n=200, MAF 2.00%), and Ossetians (n=239, MAF 0.63%). Conclusion. The results obtained in the study will be useful for developing personalized algorithms of antitumor therapy in cancer practice, including those aimed at increasing the safety of chemotherapy.
- 3 September 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (8) , 43-51
Open AccessAnalysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation
Aim. To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation. Materials and methods. The study included 1446 conditionally healthy volunteers from 9 ethnic groups. Carriage of polymorphic TPMT and DPYD gene markers was detected by the Real-Time PCR (polymerase chain reaction) method. Results. In all ethnic groups, the distribution of genotypes and alleles matched the equilibrium of Hardy-Weinberg. TPMT*3A (rs1800460) and TPMT*3C (rs1142345) were observed in heterozygous state in all investigated ethnic groups. In the Kabardinian group (n=204) the frequency of the TPMT*3A minor allele (MAF, %) was 2.94%; Balkars (n=200) 1.25%; Ossetians (n=239) 1.67%; Chuvashes (n=238) 1.89%: Mari (n=206) 1.21%; Tatars (n=141) 1.77%; Russians (n=134) 4.85%. The frequency of the TPMT*3C minor allele (MAF, %) in the Kabardinian group (n=204) MAF was 4.90%; Balkars (n=200) 1. 75%; Buryats (n=114) 0.44%; Ossetians (n=239) 1.88%; Chuvashes (n=238) 1.68%: Mari (n=206) 1.21%; Tatars (n=141) 1.42%; Russians (n=134) 4.48%. The results of the analysis of DPYD*2A polymorphism (rs3918290) demonstrated ethnic peculiarities of distribution. In the heterozygous state it was found only in the groups of Kabardins (n=204, MAF 1.22%), Balkars (n=200, MAF 2.00%), and Ossetians (n=239, MAF 0.63%). Conclusion. The results obtained in the study will be useful for developing personalized algorithms of antitumor therapy in cancer practice, including those aimed at increasing the safety of chemotherapy.